Figure 4.

Biglycan induction in L1 expressing cells is blocked when NF-κB signaling is inhibited, or an ectodomain point mutant of L1 is employed. (A) The NF-κB pathway was inhibited in L1-expressing CRC cell clones (L1 cl1 and cl2) using an shRNA that targets the p65 subunit of NF-κB (L1+shp65), or the IκB super-repressor (L1+IκB-SR), and the levels of biglycan were determined by Western blot analysis. (B) The expression of biglycan was determined by Western blotting in CRC cell clones expressing the ectodomain point mutation in L1 [L1 (H210Q) cl1 and cl2], and (C) in the L1 ectodomain point mutant (D598N) and compared to that in pcDNA3 and L1 expressing CRC cell clones. Tubulin was used for monitoring equal protein loading.